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Obstructive sleep apnea (OSA) is a common respiratory
disease characterized by abnormal collapse of the pharyngeal
airway during sleep, causing repetitive arousals and falls in
the oxygen saturation [1]. This disorder, when not correctly
treated, has been associated with higher fatal and nonfatal
cardiovascular events [2]. Also, OSA has been related to
many cardiovascular diseases (CVD) such as heart failure [3],
arrhythmias [4], pulmonary hypertension [5], and coronary
artery disease (CAD) [6]. Moreover, in recent years OSA
has emerged as a major public health problem due to its
profound impact on patients’ health. By this reason, we have
proposed this special issue about the relationship between
sleep disordered breathing (SDB) and CVD. We have sug-
gested different topics such as potential mechanisms linking
OSA to CVD, acute cardiovascular effects of OSA, impact
of OSA on natural history of CVD, cardiovascular effects of
continuous positive airway pressure (CPAP) treatment, and
therapeutic cardiovascular efficacy of emerging treatment for
OSA and central sleep apnea (CSA).
Several mechanisms are involved in the association
between OSA and CVD. In fact, enhanced sympathetic activ-
ity, oxidative stress, systemic inflammation, and endothe-
lial dysfunction contribute to this association and promote
atherogenesis. Moreover, cyclic decreases in blood oxy-
gen saturation during recurrent episodes of apnea produce
chronic intermittent hypoxia and contribute to the develop-
ment of atherosclerosis. Some hypoxia-induced transcription
factors as hypoxia-inducible factor-1 and nuclear factor-K𝛽
are activated during intermittent hypoxia and contribute to
the generation of inflammation and expression of proin-
flammatory cytokines such as tumor necrosis factor-𝛼 and
interleukin-8.
It seems that these mechanisms could have an important
impact in the occurrence of ischemic cardiac events. Hence,
CAD in OSA patients probably precludes the activation of
multiple mechanisms, such as atherosclerosis, hypertension,
and endothelial dysfunction. Likewise, OSA may influence
outcomes in patients with acute or chronic CAD, but this
effect remains controversial as results obtained from studies
have yielded discrepant data. In this way, Yumino et al. [7]
observed a higher incident of cardiac death, reinfarction,
or new revascularization in OSA patients with CAD and
compared to subjects without OSA, after a mean follow-up
period of 7 months. Nevertheless, Hagenah et al. [8] found
that OSA did not increase the risk of mortality and cardio-
vascular complications in 50 patients with stable CADafter 10
years of follow-up period.Moreover, concerning treatment of
OSA patients with CAD, CPAPmay have beneficial effects in
recurrence of ischemic cardiac disease and necessity of new
revascularization procedures but higher-evidence studies are
necessary to investigate the effect of CPAP in these subjects.
Regarding heart failure, a high prevalence of OSA and
CSA in this disorder has been observed. Also, different
therapeutic strategies such as oxygen therapy, CPAP, bilevel
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positive airway pressure (BIPAP), and adaptive servoventila-
tion (ASV) have been proposed to treat OSA in heart failure
patients. In this way, in OSA heart failure subjects, CPAPmay
improve survival, left ventricular ejection fraction, and qual-
ity of life [9–11]. Nevertheless, in heart failure CSA patients,
CPAP probably is not effective as ASV to abolish the apnea-
hypopnea index to <15 events⋅h−1 [12]. So far, it is evident
that SDB treatment has showed consistent improvements
in heart function, quality of life, and respiratory events in
patients with heart failure.However, it is necessary to evaluate
the impact of these respiratory treatments in randomized-
controlled, long-term longitudinal studies.
Finally, respecting the association between atrial arrhyth-
mia and OSA, it has been described that cardiac remodeling,
sympathetic activity, and systemic inflammation may lead to
the development of arrhythmias in these patients. Moreover,
hypoxemia and hypercapnia have an important role in the
pathogenesis of this association. However, it is necessary to
investigate the effect of CPAP treatment in atrial arrhythmias
of OSA patients.
In conclusion, sleep apnea is a high prevalence dis-
ease that has an important relationship with cardiovascular
disease. In this special issue, we have tried to make an
extensive review about mechanisms involved in the associ-
ation between ischemic cardiac disease, heart failure, and
arrhythmias with OSA. Nevertheless, we know that despite
multiple reports about OSA and cardiovascular disease, it
is yet necessary to perform higher grade evidence studies
to explore mechanisms involved in this association and the
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